Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% objective response rate and a median overall survival of 17.8 months, with an acceptable safety profile. An increase in IL-1β cytokine suggests immune activation, supporting further randomized trials. These findings offer hope for patients with limited options after multiple prior treatments.
Nanobiotix's Phase 1 trial results for JNJ-1900 (NBTXR3) in advanced melanoma provide context for health sector performance. For readers following health stocks, here is Pluang's market snapshot as of Oct 24, 2026 18:11 WIB: out of 150 priced US health stocks, 44 rose and 105 fell. Notable movers include Oscar Health Inc at USD 30.99 with a 6.99% decline, Inovio Pharmaceuticals Inc at USD 0.90 gaining 6.94%, and Hims and Hers Health Inc at USD 27.71 down 4.87%.
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 patients with advanced primary cutaneous melanoma resistant to anti-PD-1 therapy. The treatment showed a 41.7% overall response...
NEAR Protocol announced a Q3 Backers Summit scheduled for October 28. The event will focus on discussions about its House of Stake issuance proposal, updates on NEAR AI, and integration plans. Tokenomics and AI are key topics, with special guests exp...
XRP's network activity has surged, with over 1,114 XRP burned in 24 hours, marking a 27.5% increase from the previous day and the highest daily burn in over two weeks. This rise in burn rate reflects increased transaction activity on the XRP Ledger, ...
